References
- CariouBCharbonnelBStaelsBThiazolidinediones and PPARγ agonists: time for a reassessmentTrends Endocrinol Metab201223520521522513163
- KungJHenryRRThiazolidinedione safetyExpert Opin Drug Saf201211456557922616948
- HomePDPocockSJBeck-NielsenHRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancet200937396812125213519501900
- LincoffAMWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsJAMA2007298101180118817848652
- WatkinsPBWhitcombRWHepatic dysfunction associated with troglitazoneN Engl J Med1998338139169179518284
- NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
- LagoRMSinghP PNestoRWCongestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trialsLancet200737095931129113617905165
- DorkhanMDenckerMStagmoMGroopLEffect of pioglitazone versus insulin glargine on cardiac size, function and measures of fluid retention in patients with type 2 diabetesCardiovasc Diabetol20098152019298680
- SinghSLokeYFurbergCLong-term risk of cardiovascular events with rosiglitazone: a meta-analysisJAMA2007298101189119517848653
- DormandyJACharbonnelBEcklandDJASecondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trialLancet200536694931279128916214598
- FanarowGCApproach to the management of diabetic patients with heart failure: role of thiazolidinedionesAm Heart J2004148455155815459582
- MasoudiFAInzucchiSEWangYHavranekE PFoodyJMKrumholzHMThiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure. An observational studyCirculation2005111558359015699279
- HaffnerSMLehtoSRonnemaaTPyoralaKLaaksoMMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med199833942292349673301
- BrenerSJLytleB WCasserlyI PTopolEJLauerMSPropensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary disease and high-risk featuresCirculation2004109192290229515117846
- ScholteAJSchuijfJDKharagjitsinghAVPrevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetesHeart200894329029517646190
- WallerBFPalumboPJLieJTRobertsWCStatus of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjectsAm J Med19806944985067424939
- GuKCowieCCHarrisMIDiabetes and decline in heart disease mortality in US adultsJAMA1999281141291129710208144
- NissenSENichollsSJWolskiKComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA2008299131561157318378631
- KuusistoJMykkänenLPyöräläKLaaksoMHyperinsulinemic microalbuminuria: a new risk indicator for coronary heart diseaseCirculation19959138318377828312
- EastmanRCKeenHThe impact of cardiovascular disease on people with diabetes: the potential for preventionLancet1997350Suppl 1SI29SI329250281
- MattockMBMorrishNJVibertiGKeenHFitzgeraldA PJacksonGProspective study of microalbuminuria as predictor of mortality in NIDDMDiabetes19924167367411587400
- HanefeldMBrunettiPSchernthanerGHMatthewsDRCharbonnelBHOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesDiabetes Care200427114114714693980
- AgrawalBWolfKBergerALuftFCEffect of antihypertensive treatment on qualitative estimates of microalbuminuriaJ Hum Hypertens19961085515558895040
- NakamuraTUshiyamaCOsadaSHaraMShimadaNKoideHPioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuriaMetabolism200150101193119611586492
- KoskinenPManttariMManninenVHuttunenJKHeinonenO PFrickMHCoronary heart disease incidence in NIDDM patients in the Helsinki Heart StudyDiabetes Care19921578208251516498
- HaffnerSMDyslipidemia management in adults with diabetesDiabetes Care200427Suppl 1S68S7114693930
- GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052871547155415983299
- BerhanuPKipnesMSKhanMAEffects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapyDiab Vasc Dis Res200631394416784180
- DavidsonMMeyerPMHaffnerSIncreased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitusCirculation2008117162123213018413496
- DerosaGCiceroAFD’AngeloAEffects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, doubleblind, controlled clinical trialClin Ther200628567968816861090
- HanefeldMMarxNPfütznerAAnti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT StudyJ Am Coll Cardiol200749329029717239709
- KaragiannisEPfütznerAForstTThe IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditionsDiabetes Technol Ther200810320621218473695
- ForstTKaragiannisELübbenGPleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery diseaseAtherosclerosis2008197131131717588584
- HondaTKaikitaKTsujitaKPioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disordersJ Mol Cell Cardiol200844591592618436235
- LiJLangMJMaoXBTianLFengYBAntiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of ratCardiovasc Drugs Ther200822428329118470603
- YeYLinYManickavasagamSPerez-PoloJRTieuBCBirnbaumYPioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout miceAm J Physiol Heart Circ Physiol20082956H2436H244618931027
- WangHZhuQ WYePPioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2Biosci Trends20126632533223337792
- MeierCKraenzlinMEBodmerMJickSSJickHMeierCRUse of thiazolidinediones and fracture riskArch Intern Med2008168882082518443256